Cel Sci CORP 8-K filings

CEL-SCI Corporation has successfully closed a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, raising $2.5 million in gross proceeds.

CEL-SCI Corporation has entered a strategic distribution and revenue-sharing agreement with Saudi Amarox Co. to commercialize its immunotherapy candidate, Multikine, in Saudi Arabia.

CEL-SCI Corporation announced the pricing of a public offering of 6,000,000 shares of common stock at $1.20 per share, raising approximately $7.2 million in gross proceeds.

CEL-SCI Corporation's Board of Directors has adopted a Shareholder Rights Agreement, commonly known as a 'poison pill,' to protect against coercive takeover attempts and ensure fair value for shareholders.

CEL-SCI Corporation has amended its Shareholder Rights Agreement, extending its expiration date to October 30, 2030, a move designed to protect against hostile takeovers.

CEL-SCI Corporation successfully closed a $10 million public offering to fund the continued development of its cancer immunotherapy, Multikine.

CEL-SCI Corporation has filed for Breakthrough Medicine Designation for its drug Multikine with the Saudi Food and Drug Authority, partnering with Dallah Pharma for commercialization.

CEL-SCI Corporation, a clinical-stage cancer immunotherapy company, successfully closed a best-efforts offering of 1.5 million common shares, raising approximately $5.7 million in gross proceeds to fund the continued development of its lead product, Multikine, and for general corporate purposes.

CEL-SCI Corporation announced the successful pricing and closing of a public offering of 2 million common shares at $2.50 each, generating $5 million in gross proceeds to advance its lead cancer immunotherapy, Multikine.

CEL-SCI Corporation held its annual shareholder meeting on May 19, 2025, where directors were elected and several proposals, including the adoption of new stock option and bonus plans, a common stock combination, and the appointment of an independent accounting firm, were approved.

CEL-SCI Corporation has priced a $2.56 million offering of common stock and pre-funded warrants to fund Multikine development and for general corporate purposes.

CEL-SCI Corporation successfully priced and closed a public offering, raising approximately $5 million to support the development of its cancer immunotherapy, Multikine.

CEL-SCI Corporation has appointed Patricia B. Prichep, previously Senior Vice President of Operations, as its new Chief Financial and Operations Officer, effective November 13, 2024.

CEL-SCI Corporation has appointed Dr. Nabil F. Saba, a renowned expert in head and neck cancer, to lead their upcoming confirmatory Phase III clinical trial for Multikine.

CEL-SCI reported that its Multikine treatment increased the 5-year survival rate to 82.6% in a specific group of head and neck cancer patients, with a 73% reduction in the risk of death.

CEL-SCI Corporation has successfully priced a $10.8 million offering of common stock and pre-funded warrants to fund the continued development of Multikine and for general corporate purposes.

CEL-SCI reports positive results from a bias analysis of its Phase 3 Multikine study, showing no significant imbalances between treatment and control groups, supporting the drug's efficacy in head and neck cancer.

CEL-SCI's Multikine shows a significant increase in overall survival for head and neck cancer patients with low PD-L1 expression, cutting the risk of death in half compared to standard care.

CEL-SCI Corporation has appointed Mario Gobbo, a seasoned finance professional with extensive experience in healthcare and energy, to its Board of Directors.

CEL-SCI Corporation held its annual shareholder meeting on April 19, 2024, electing directors, approving a new stock option plan, and ratifying its accounting firm.

CEL-SCI Corporation successfully closed a public offering of common stock, raising $7.75 million to support the development of its cancer immunotherapy, Multikine.